@article{Oerlemans_2021,<br/><span class="tab"></span> title={Repurposing the HCV NS3–4A protease drug boceprevir as COVID-19 therapeutics},<br/><span class="tab"></span> volume={12},<br/><span class="tab"></span> ISSN={2632-8682},<br/><span class="tab"></span> url={http://dx.doi.org/10.1039/d0md00367k},<br/><span class="tab"></span> DOI={10.1039/d0md00367k},<br/><span class="tab"></span> number={3},<br/><span class="tab"></span> journal={RSC Medicinal Chemistry},<br/><span class="tab"></span> publisher={Royal Society of Chemistry (RSC)},<br/><span class="tab"></span> author={Oerlemans,<br/><span class="tab"></span> Rick and Ruiz-Moreno,<br/><span class="tab"></span> Angel Jonathan and Cong,<br/><span class="tab"></span> Yingying and Dinesh Kumar,<br/><span class="tab"></span> Nilima and Velasco-Velazquez,<br/><span class="tab"></span> Marco A. and Neochoritis,<br/><span class="tab"></span> Constantinos G. and Smith,<br/><span class="tab"></span> Jolanda and Reggiori,<br/><span class="tab"></span> Fulvio and Groves,<br/><span class="tab"></span> Matthew R. and Dömling,<br/><span class="tab"></span> Alexander},<br/><span class="tab"></span> year={2021},<br/><span class="tab"></span> pages={370–379} }